Welcome to the UPF Digital Repository

Consensus on the statin of choice in patients with impaired glucose metabolism: results of the DIANA study

Show simple item record

dc.contributor.author Millán Núñez-Cortés, Jesús
dc.contributor.author Cases Amenós, Aleix
dc.contributor.author Ascaso Gimilio, Juan Francisco
dc.contributor.author Barrios Alonso, Vivencio
dc.contributor.author Pascual Fuster, Vicente
dc.contributor.author Pedro-Botet, Juan Carlos
dc.contributor.author Pintó Sala, Xavier
dc.contributor.author Serrano Cumplido, Adalberto
dc.date.accessioned 2017-11-15T08:40:35Z
dc.date.available 2017-11-15T08:40:35Z
dc.date.issued 2017
dc.identifier.citation Millán Núñez-Cortés J, Cases Amenós A, Ascaso Gimilio JF, Barrios Alonso V, Pascual Fuster V, Pedro-Botet Montoya JC. Et al. Consensus on the statin of choice in patients with impaired glucose metabolism: results of the DIANA study. Am J Cardiovasc Drugs. 2017 Apr;17(2):135-142. DOI: 10.1007/s40256-016-0197-9
dc.identifier.issn 1175-3277
dc.identifier.uri http://hdl.handle.net/10230/33226
dc.description.abstract INTRODUCTION AND OBJECTIVES: Despite the recognized clinical benefit of statins on cardiovascular prevention, providing correct management of hypercholesterolaemia, possible adverse effects of their use cannot be disregarded. Previously published data shows that there is a risk of developing diabetes mellitus or experiencing changes in glucose metabolism in statin-treated patients. The possible determining factors are the drug characteristics (potency, dose), patient characteristics (kidney function, age, cardiovascular risk and polypharmacy because of multiple disorders) and the pre-diabetic state. METHODS: In order to ascertain the opinion of the experts (primary care physicians and other specialists with experience in the management of this type of patient) we conducted a Delphi study to evaluate the consensus rate on diverse aspects related to the diabetogenicity of different statins, and the factors that influence their choice. RESULTS: Consensus was highly significant concerning aspects such as the varying diabetogenicity profiles of different statins, as some of them do not significantly worsen glucose metabolism. There was an almost unanimous consensus that pitavastatin is the safest statin in this regard. CONCLUSIONS: Factors to consider in the choice of a statin regarding its diabetogenicity are the dose and patient-related factors: age, cardiovascular risk, diabetes risk and baseline metabolic parameters (which must be monitored during the treatment), as well as kidney function.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher SpringerOpen
dc.rights This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
dc.subject.other Diabetis -- Tractament
dc.title Consensus on the statin of choice in patients with impaired glucose metabolism: results of the DIANA study
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1007/s40256-016-0197-9
dc.subject.keyword Diabetes
dc.subject.keyword Impaired glucose tolerance Consensus
dc.subject.keyword Statins
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking